35128 Cerebrovascular accident events associated with IL-23 inhibition: Pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) from the RADAR (Research on Adverse Drug Events And Reports) Program

Abstract

Background: IL-23 inhibitors, risankizumab, guselkumab, and tildrakizumab, are approved systemic therapies for adults with moderate-to-severe plaque psoriasis. Although an increased risk for cerebrovascular accidents (CVAs) has been reported with exposure to combined IL-12/IL-23 inhibition in patients with cardiovascular risk, such evidence for IL-23 inhibition as monotherapy remains unaddressed. The aim of this study was to determine if a safety signal is detectable in the FAERS database for IL-23 inhibitors and subsequent CVAs.